Phaseline

Targets › CLDN18A2

CLDN18A2: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: the race on CLDN18A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing BiotechEBNK-1822H2
Dual-target CLDN18.2/HER2 CAR-NK cells
CLDN18A2, ERBB2Phase 1Recurrent or Metastatic Esophageal AdenocarcinomaMar 2027

Conditions

Recurrent or Metastatic Esophageal Adenocarcinoma (1)

Modalities

mixed (1)

Companies

Beijing Biotech (1)

Related targets

ERBB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.